Glenmark Pharmaceuticals posted 16% growth in December-quarter profit on strong India formulations demand, improved North America performance and margin expansion, with EBITDA surging 45% and regulatory clearance enabling manufacturing restart at its US facility.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets